The latest price target for Inhibikase Therapeutics (NASDAQ:IKT) was reported by Cantor Fitzgerald on December 11, 2025. The analyst firm set a price target for $4.00 expecting IKT to rise to within 12 months (a possible 158.06% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Inhibikase Therapeutics (NASDAQ:IKT) was provided by Cantor Fitzgerald, and Inhibikase Therapeutics initiated their overweight rating.

There is no last upgrade for Inhibikase Therapeutics

The last downgrade for Inhibikase Therapeutics Inc happened on February 12, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for Inhibikase Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibikase Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibikase Therapeutics was filed on December 11, 2025 so you should expect the next rating to be made available sometime around December 11, 2026.

While ratings are subjective and will change, the latest Inhibikase Therapeutics (IKT) rating was a initiated with a price target of $0.00 to $4.00. The current price Inhibikase Therapeutics (IKT) is trading at is $1.55, which is within the analyst’s predicted range.